Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). by Chiang, Chern-En et al.
Available at:
http://hdl.handle.net/2078.1/170699
[Downloaded 2019/04/19 at 01:07:10 ]
"Suboptimal Control of Lipid Levels: Results from 29 Countries
Participating in the Centralized Pan-Regional Surveys on
the Undertreatment of Hypercholesterolaemia (CEPHEUS)."
Chiang, Chern-En ; Ferrières, Jean ; Gotcheva, Nina N. ; Raal, Frederick J. ;
Shehab, Abdulla ; Sung, Jidong ; Henriksson, Karin M. ; Hermans, Michel
Abstract
Aim: Five multicentre, cross-sectional Centralized Pan-Regional Surveys on the
Undertreatment of Hypercholesterolaemia (CEPHEUS) were conducted in 29
countries across Asia, Western Europe, Eastern Europe, the Middle East, and
Africa. The surveys assessed the current use and efficacy of lipid-lowering drugs
(LLDs) worldwide and identified possible patient and physician characteristics
associated with failure to attain low-density lipoprotein cholesterol (LDL-C) goals.
The aim of this analysis was to consolidate the global results from these surveys.
Methods: The surveys involved patients aged ≥18 years who had been prescribed
LLDs for at least 3 months without dose changes for at least 6 weeks. A single
visit was scheduled for data collection, including fasting plasma lipid and glucose
levels. Cardiovascular risk profile and LDL-C goal attainment were assessed
according to the 2004 updated US National Cholesterol Education Program Adult
Treatment Panel III guidelines. Results: In to...
Document type : Article de périodique (Journal article)
Référence bibliographique
Chiang, Chern-En ; Ferrières, Jean ; Gotcheva, Nina N. ; Raal, Frederick J. ; Shehab, Abdulla ; et.
al. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized
Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).. In: Journal
of Atherosclerosis and Thrombosis, Vol. 23, no. 5, p. 567-587 (2016)
DOI : 10.5551/jat.31179
1Journal of Atherosclerosis and Thrombosis　Vol.22, No. ●
Original Article
Suboptimal Control of Lipid Levels: Results from 29 Countries 
Participating in the Centralized Pan-Regional Surveys on the 
Undertreatment of Hypercholesterolaemia (CEPHEUS)
Chern-En Chiang1, Jean Ferrières2, Nina N Gotcheva3, Frederick J Raal4, Abdulla Shehab5, Jidong Sung6,
Karin M Henriksson7, 8 and Michel P Hermans9
1General Clinical Research Center, Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, 
Taipei, Taiwan
2Department of Cardiology, Toulouse University Hospital, Toulouse, France
3Department of Cardiology, National Heart Hospital, Sofia, Bulgaria
4Faculty of Health Sciences, Johannesburg Hospital, Johannesburg, South Africa
5Department of Internal Medicine, United Arab Emirates University, Al-Ain, United Arab Emirates
6Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
7AstraZeneca Gothenburg, Mölndal, Sweden
8Department of Medical Sciences, Uppsala University, Uppsala, Sweden
9Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Aim: Five multicentre, cross-sectional Centralized Pan-Regional Surveys on the Undertreatment of 
Hypercholesterolaemia (CEPHEUS) were conducted in 29 countries across Asia, Western Europe, 
Eastern Europe, the Middle East, and Africa. The surveys assessed the current use and efficacy of 
lipid-lowering drugs (LLDs) worldwide and identified possible patient and physician characteristics 
associated with failure to attain low-density lipoprotein cholesterol (LDL-C) goals. The aim of this 
analysis was to consolidate the global results from these surveys.
Methods: The surveys involved patients aged ≥18 years who had been prescribed LLDs for at least 3 
months without dose changes for at least 6 weeks. A single visit was scheduled for data collection, 
including fasting plasma lipid and glucose levels. Cardiovascular risk profile and LDL-C goal attain-
ment were assessed according to the 2004 updated US National Cholesterol Education Program 
Adult Treatment Panel III guidelines.
Results: In total, 35 121 patients (mean age: 60.4 years) were included, and 90.3% had been pre-
scribed statin monotherapy. Overall, only 49.4% of patients reached their recommended LDL-C 
level. LDL-C goals were attained in 54.8% (5084/9273) and 22.8% (3287/14 429) of patients were 
at high and very high cardiovascular risk, respectively. Factors associated with an increased likelihood 
of LDL-C goal attainment were lower baseline cardiovascular risk; presence of diabetes mellitus, 
hypertension, or history of cardiovascular disease; and treatment with simvastatin, atorvastatin, or 
rosuvastatin (vs. all other LLDs).
Conclusion: LDL-C goal attainment in patients taking LLDs is suboptimal worldwide, particularly 
in patients at high and very high cardiovascular risk.
J Atheroscler Thromb, 2015; 22: 000-000.
Key words: Cardiovascular disease, Hypercholesterolaemia, Lipidlowering drugs, 
Low-density lipoprotein cholesterol, Undertreatment
Introduction
Cardiovascular (CV) disease is the leading cause 
of death globally and represents a substantial eco-
nomic burden1, 2). Epidemiological studies have shown 
that elevated serum lipid and low-density lipoprotein 
cholesterol (LDL-C) levels, in particular, are strongly 
associated with an increased risk of incident CV dis-
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pines, South Korea, Taiwan, Thailand, and Viet-
nam)23, 26), Western Europe (Belgium, Finland, France, 
Greece, Ireland, Luxembourg, Netherlands, and Tur-
key)22, 27, 28), Eastern Europe (Bulgaria, Poland, and 
Russia)20), the Middle East (United Arab Emirates, 
Bahrain, Jordan, Kuwait, Oman, Qatar, and Saudi 
Arabia)21, 25), and Africa (Algeria, Egypt. and South 
Africa)24). In each country, the study protocol was 
reviewed and approved by the Institutional Review 
Board and Ethics Committee governing each partici-
pating center. The surveys were performed in accor-
dance with the Declaration of Helsinki and the Inter-
national Conference on Harmonisation guidelines for 
Good Clinical Practice 29), and all participating 
patients provided written informed consent before 
enrolment.
Each survey was a single-visit study and recruit-
ment was carried out in two stages. In the first stage, 
physicians with experience of treating dyslipidaemia 
were invited to participate. Physicians who agreed to 
participate were asked to complete a questionnaire 
about their general attitude toward the diagnosis of 
hypercholesterolaemia, their perception of existing 
guidelines, and their knowledge about available treat-
ment options (Supplemental Fig.1). In the second 
stage, eligible patients who attended a regular sched-
uled physician visit were consecutively invited to par-
ticipate in the study. Patients were eligible to partici-
pate if they were ≥18 years and had been receiving 
LLDs for at least 3 months without dose changes for 
at least 6 weeks. Patients were excluded if they were 
found to have participated in any interventional clini-
cal study in the preceding 90 days, were unable or 
unwilling to provide informed consent, or were per-
sonally involved in the conduct of the surveys. In all 
countries except France, before being assessed by the 
physician, patients also completed a questionnaire, the 
aim of which was to assess their personal perception of 
hypercholesterolaemia, their current LLD regimen, 
their adherence to this regimen, and their satisfaction 
with the treatment (Supplemental Fig.2).
For each individual, physicians also completed a 
patient record form, which included information on 
the patient’s demographics, current LLD therapy, and 
reason for initiating LLD therapy. Physicians also 
recorded the presence of known CV risk factors, such 
as smoking, diabetes mellitus, family history of pre-
mature coronary heart disease (CHD; defined as hav-
ing a first-degree relative with clinical CHD or sudden 
death before the age of 55 years for men or 65 years 
for women), hypertension (defined as blood pressure 
≥140/90 mmHg or current use of antihypertensive 
medication), any CV history, and presence of meta-
ease in many populations worldwide3, 4).
Most guidelines include the reduction of LDL-C 
levels as a primary therapeutic target for the reduction 
of CV risk in both primary and secondary prevention, 
and they recommend LDL-C goals that are based on 
the CV risk category of the individual patient5-8). For 
example, the 2004 updated US National Cholesterol 
Educational Program Adult Treatment Panel III 
(NCEP ATP III) guidelines recommend a therapeutic 
LDL-C goal of ＜2.6 mmol/L (100 mg/dL) for those 
at high CV risk, with the option to lower the goal to 
＜1.8 mmol/L (70 mg/dL) for individuals at very high 
CV risk, and ＜3.4 mmol/L (130 mg/dL) for those at 
moderately high CV risk5). The Joint European Task 
Force has issued similar guidelines and recommends 
LDL-C levels of ＜1.8 mmol/L (70 mg/dL), ＜2.6 
mmol/L (100 mg/dL), and ＜3.0 mmol/L (115 mg/
dL) for patients at very high, high, and moderate/low 
CV risk, respectively8).
Statins are the mainstay of lipid-lowering drug 
(LLD) therapy and have been shown to reduce both 
LDL-C levels and CV risk in clinical trials9-16). Despite 
the significant increase in the number of patients 
treated with statins and other LLDs over the past 
decade, surveys have shown that relatively few indi-
viduals eligible for treatment attain their recommended 
LDL-C level17-19).
Aim
In order to assess the use and efficacy of LLD 
therapy worldwide, several Centralized Pan-Regional 
Surveys on the Undertreatment of Hypercholesterol-
aemia (CEPHEUS) were conducted between 2006 
and 2010. In total, 29 countries were included, and 
patient and physician characteristics associated with 
failure to attain recommended LDL-C levels were also 
assessed20-28). Here we have consolidated the global 
results and analyzed LLD use and LDL-C goal attain-
ment worldwide.
Methods
Study Design and Population
Five multicentre, prospective, cross-sectional 
CEPHEUS studies were conducted in 29 countries 
across Asia (Hong Kong, Indonesia, Malaysia, Philip-
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at least one question) and for whom a current lipid 
profile dataset was available (i.e., valid measurements 
for total cholesterol, LDL-C, HDL-C, and triglycer-
ides). In total, 35 121 patients from 29 countries were 
included. For the assessment of determinants of 
LDL-C goal attainment, patients who had not com-
pleted the patient questionnaire were excluded; there-
fore, the multivariate analysis included 32 782 patients 
from 28 countries (Fig.1).
Definitions of CV Risk Categories and LDL-C 
Goals
The CV risk category and attainment of LDL-C 
goal for each patient were assessed according to the 
2004 updated NCEP ATP III guidelines5). Patients 
were considered to be at very high CV risk if they had 
established CHD and severe and persistent CV risk 
factors, high CV risk if they had established CHD or 
CHD risk equivalents (i.e., abdominal aortic aneu-
rysm, diabetes mellitus, peripheral vascular disease, 
symptomatic carotid artery disease or chronic kidney 
disease) or a 10-year Framingham absolute risk score 
＞20%30), moderate CV risk if they had two or more 
CV risk factors or a 10-year Framingham absolute risk 
bolic syndrome. Patients with metabolic syndrome 
were those with three or more of the following: fasting 
plasma triglyceride levels of at least 1.7 mmol/L (150 
mg/dL), high-density lipoprotein cholesterol (HDL-
C) levels ＜1.0 mmol/L (40 mg/dL) for men and ＜1.3 
mmol/L (50 mg/dL) for women, blood pressure at 
least 130/85 mmHg, a fasting plasma glucose level of 
at least 5.6 mmol/L (100 mg/dL), and enlarged waist 
circumference (the definition of enlarged waist cir-
cumference varied across the regional CEPHEUS 
studies20-28); for this statistical analysis, it was defined 
as a waist circumference of at least 90 cm for men and 
at least 80 cm for women). Examination by the physi-
cian was limited to measurement of height, weight, 
waist circumference, and blood pressure. An overnight 
fasting blood sample was drawn to determine glucose 
and lipid (total cholesterol, HDL-C, triglycerides, and 
LDL-C) concentrations. Local laboratories were used 
at each study location for the analysis of LDL-C lev-
els, which were either directly quantified by colorime-
try or calculated using the Friedewald equation.
For the analysis of LDL-C goal attainment, the 
study cohort consisted of all individuals whose physi-
cian returned the physician questionnaire (answering 
Fig.1. Study cohort.
LDL-C goal attainment was assessed in all patients who provided their informed consent and 
for whom full lipid profiles and completed physician questionnaires were available. Patients 
who had not completed a questionnaire were excluded from the multivariate analysis.
LDL-C= low-density lipoprotein cholesterol.
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your cholesterol levels ? (more than once a week/once a 
week/once every 2 weeks/once a month or less), and 
In general, do you feel satisfied about the way your high 
cholesterol has been treated ? (yes/no) from the patient 
questionnaire (Supplemental Fig.2); and the answer 
to the question I feel frustrated that I am not always 
able to effectively treat my patients with CV disorders (1, 
disagree strongly; 2/3/4/5, agree strongly) from the 
physician questionnaire (Supplemental Fig.1).
Results
Patient Characteristics
Patient demographics and baseline characteris-
tics, overall and by region, are shown in Table 1. The 
mean age of the study population was 60.4 years. The 
mean age was lowest in the Middle East (56.1 years) 
and highest in Western Europe (63.3 years). More 
men than women were included, both overall (men: 
55.1%) and in each region (between-region range 
[BRR] for men: 51.2% –58.7%). The mean body 
mass index (BMI) was 28.4 kg/m2, and 74.4% of 
patients were overweight or obese (BMI ≥25 kg/m2). 
The proportion of patients who were overweight or 
obese was highest in the Middle East (86.3%) and 
lowest in Asia (54.8%). The prevalence of hyperten-
sion (blood pressure ≥140/90 mmHg or current use 
of antihypertensive medication) was high (72.8%, 
BRR: 62.8%–89.2%), and 66.3% of patients had 
elevated blood pressure (≥130/85 mmHg). The pro-
portions of patients with elevated blood pressure were 
similar in Asia, the Middle East, and Africa (61.0% –
62.1%), but were higher in Western and Eastern 
Europe (71.8% and 71.0%, respectively). Current 
smokers represented 18.0% (BRR: 13.3% –21.6%) of 
the study population, and 27.8% (BRR: 21.9% –
32.7%) of patients had a family history of early-onset 
CHD. According to the 2004 updated NCEP ATP III 
guidelines, 41.6% of participants were at very high 
CV risk (BRR: 33.0%–64.0%), 35.1% at high/mod-
erately high CV risk (BRR: 19.1%–48.4%), 11.9% at 
moderate CV risk (BRR: 7.9% –13.8%), and 11.4% 
at low CV risk (BRR: 1.1%–20.9%).
LLD Indication and Current Treatment
Overall, patients had been on LLD therapy for a 
mean of 3.9 years (standard deviation: 3.9 years; 
range: 0 –47 years) (Table 2). Patients who were pre-
scribed LLDs for primary CV disease prevention com-
prised 57.5% of the overall population (BRR: 46.2%–
71.5%) and those who were prescribed LLDs for sec-
ondary CV disease prevention comprised 40.2% 
(BRR: 27.3% –51.7%). For the remaining patients 
score between 10% and 20%30), and low CV risk if 
they had no more than one CV risk factor. For 
patients at very high CV risk, the 2004 updated 
NCEP ATP III LDL-C goal was ＜1.8 mmol/L (70 
mg/dL); for patients at high risk, the goal was ＜2.6 
mmol/L (100 mg/dL); for patients at moderate/mod-
erately high risk, the goal was ＜3.4 mmol/L (130 mg/
dL); and for patients at low risk, the goal was ＜4.1 
mmol/L (160 mg/dL).
Statistical Analysis
A two-level logistic regression model with patients 
at the first level and physicians as a random effect at 
the second level was used to determine the factors 
affecting attainment of LDL-C goals. In the first step, 
patient-related factors were screened in univariate 
analyses by means of a logistic model, and physician-
related factors were screened in univariate analyses by 
means of a generalized linear mixed model (GLMM) 
with physician as a random effect. GLMM was carried 
out using the GLIMMIX procedure of the SAS system 
(SAS Institute, Carey, NC, USA). Following this, 
potential predictors were selected for inclusion in the 
multivariate analysis according to their statistical sig-
nificance in the univariate analyses (p＜0.01), the 
Bayesian information criterion, and the number of 
patients for whom data were available for each vari-
able. In the second step, associations were assessed by 
means of a multivariate, multilevel logistic model 
using a backward stepwise procedure; a full model 
with all selected variables from the univariate analysis 
was constructed, and at each step, the least significant 
variable was removed until all parameters reached a 
level of significance of p＜0.01.
Associations were assessed on the basis of the 
estimated odds ratios (ORs) and their corresponding 
95% confidence intervals (CIs) and p values. For con-
tinuous variables, ORs were calculated for a change of 
one unit of the variable. Following this strategy, the 
final model was adjusted for the following variables: 
CV risk category according to the 2004 updated 
NCEP ATP III guidelines; country; type of LLD ther-
apy; sex; age; presence of CVD, metabolic syndrome, 
hypertension, diabetes mellitus, and family history of 
early-onset CHD; indication for LLD therapy; smok-
ing status; answers to the following questions: Did 
your doctor give you a target cholesterol level to aim for ? 
(yes/no), I am frustrated that I still do not know whether 
my tablets have been effective enough in lowering my cho-
lesterol (agree/disagree/don’t know or not applicable), I 
always take my tablets to lower my cholesterol every day 
(agree/disagree/don’t know or not applicable), How 
often do you think you can miss a tablet without affecting 
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Table 1. Patient demographics and baseline characteristics, overall and by region
Total
(N=35 121)
Asia
(n=7489)
Western Europe
(n=12 319)
Eastern Europe
(n=4654)
Middle East
(n=5850)
Africa
(n=4809)
Age (years)
＜40
40–54
55–69
≥70
Mean±SD
Sex
Male
Female
BMI (kg/m2)
＜25
25–29
≥30
Mean±SD
Waist circumference (cm)
＜90 (men), ＜80 (women)
≥90 (men), ≥80 (women)
Mean±SD
Blood pressure (mmHg)
SBP/DBP ＜130/85
SBP/DBP ≥130/85
SBP mean±SD
DBP mean±SD
CV risk factors
Metabolic syndrome
Diabetes mellitus
Hypertension＊
Smoking†
Family history of early-onset CHD‡
Age§
CV disease history
CHD
Peripheral arterial disease
Carotid artery disease
Abdominal aortic aneurysm
ACVD
Ischaemic stroke
CV risk category¶
Very high
High
Moderately high
Moderate
Low
1401 (4.0)
8914 (25.7)
16 285 (46.9)
8128 (23.4)
60.4±11.7
19 153 (55.1)
15 601 (44.9)
8865 (25.6)
14 642 (42.3)
11 093 (32.1)
28.41±5.26
5577 (16.3)
28 680 (83.7)
97.2±13.5
11 691 (33.7)
23 002 (66.3)
133.2±16.7
79.9±9.8
19 852 (58.1)
13 230 (38.1)
25 304 (72.8)
6245 (18.0)
9642 (27.8)
28 858 (83.1)
13 639 (39.3)
2401 (6.9)
407 (5.5)
56 (0.8)
2229 (8.5)
65 (5.6)
14 429 (41.6)
9273 (26.7)
2904 (8.4)
4142 (11.9)
3954 (11.4)
231 (3.1)
1909 (25.5)
3485 (46.6)
1859 (24.8)
61.0±11.3
4160 (55.6)
3328 (44.4)
3361 (45.2)
3083 (41.4)
995 (13.4)
25.84±4.07
2132 (28.6)
5313 (71.4)
90.6±10.2
2913 (39.0)
4559 (61.0)
131.8±17.4
78.9±11.1
4444 (60.0)
3286 (44.2)
6305 (84.2)
1617 (21.6)
2120 (28.3)
6423 (85.8)
3547 (47.6)
306 (4.1)
407 (5.5)
56 (0.8)
NA
NA
3664 (49.0)
2151 (28.8)
560 (7.5)
1018 (13.6)
86 (1.1)
298 (2.5)
2231 (18.6)
5624 (46.8)
3860 (32.1)
63.3±11.2
6621 (55.0)
5407 (45.0)
3052 (25.5)
5638 (47.1)
3281 (27.4)
27.91±4.64
1811 (15.3)
9992 (84.7)
97.0±13.2
3376 (28.2)
8606 (71.8)
134.5±15.4
80.0±8.7
5942 (49.4)
2749 (22.9)
7544 (62.8)
2216 (18.4)
3450 (28.8)
10 689 (89.0)
3499 (29.1)
1168 (9.7)
NA
NA
990 (8.3)
NA
3960 (33.0)
2353 (19.6)
1514 (12.6)
1655 (13.8)
2511 (20.9)
146 (3.1)
985 (21.1)
2419 (52.0)
1104 (23.7)
61.4±10.7
2377 (51.2)
2264 (48.8)
774 (16.7)
2099 (45.3)
1761 (38.0)
29.10±4.62
625 (13.5)
4008 (86.5)
97.2±13.0
1342 (29.0)
3292 (71.0)
134.3±15.6
82.2±9.2
2753 (59.3)
1179 (22.9)
4151 (89.2)
860 (18.5)
1523 (32.7)
4031 (86.7)
2789 (59.9)
483 (10.4)
NA
NA
837 (18.0)
NA
2973 (64.2)
536 (11.6)
349 (7.5)
554 (12.0)
221 (4.8)
354 (6.4)
2284 (39.2)
2487 (42.7)
704 (12.1)
56.1±11.4
3422 (58.7)
2404 (41.3)
792 (13.7)
2001 (34.5)
3007 (51.8)
31.03±6.14
463 (8.2)
5209 (91.8)
103.0±13.9
2252 (38.6)
3585 (61.4)
131.8±18.1
78.9±10.2
3904 (67.8)
3631 (62.2)
3861 (66.2)
918 (15.7)
1277 (21.9)
4224 (72.5)
1923 (32.9)
165 (2.8)
NA
NA
204 (3.5)
NA
1929 (33.1)
2586 (44.3)
239 (4.1)
463 (7.9)
616 (10.6)
372 (7.8)
1505 (31.7)
2270 (47.8)
601 (12.7)
56.4±11.7
2573 (53.9)
2198 (46.1)
886 (18.6)
1821 (38.3)
2049 (43.1)
29.81±5.74
546 (11.6)
4158 (88.4)
101.0±14.4
1808 (37.9)
2960 (62.1)
132.6±17.6
79.9±10.2
2809 (64.9)
2385 (50.0)
3443 (72.2)
634 (13.3)
1272 (26.7)
3491 (73.5)
1881 (39.4)
279 (5.8)
NA
NA
198 (5.5)
65 (5.6)
1903 (39.9)
1647 (34.6)
242 (5.1)
452 (9.5)
520 (10.9)
ACVD=atherosclerotic cerebrovascular disease; BMI=body mass index; CHD=coronary heart disease; CV=cardiovascular; DBP=diastolic blood 
pressure; NA=not available (data not collected); NCEP ATP III=US National Cholesterol Educational Program Adult Treatment Panel III; 
SBP= systolic blood pressure; SD= standard deviation.
Numbers are n (%) unless otherwise stated and are based on patients with non-missing data.
＊Blood pressure ≥140/90 mmHg or on antihypertensive medication.
†Any smoking in the past month.
‡First-degree relative(s) with clinical coronary heart disease or sudden death at age ＜55 years for men and ＜65 years for women.
§Age ≥45 years for men and ≥55 years for women.
¶As defined by the 2004 updated NCEP ATP III guidelines5).
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LDL-C goal were higher for women than for men 
(51.9% vs. 47.4%).
Attainment of LDL-C goal varied according to 
the CV risk category (Fig.3); 89.8% (BRR: 79.1% –
91.1%) of individuals at low CV risk attained their 
LDL-C goal compared with only 54.8% (BRR: 
34.1%–65.7%) and 22.8% (BRR: 9.8% –36.9%) of 
patients in the high and very high CV risk categories, 
respectively.
The type of LLD therapy also had an impact on 
the proportions of patients attaining their LDL-C goal 
(Fig.4). Overall, the highest proportion of patients 
attaining their LDL-C goal was observed for those 
who were prescribed statin monotherapy (49.7%), fol-
lowed by those who were prescribed any combination 
therapy (46.9%) and fibrate monotherapy (46.0%). 
The proportion of patients attaining their LDL-C goal 
was lowest in those who received any other monother-
apy (33.1%), although it should be noted that this 
group included only 130 individuals.
Determinants of LDL-C Goal Attainment
The factors significantly affecting LDL-C goal 
attainment in the multivariate adjusted model are 
summarized in Fig.5. In this model, women were less 
(2.3%, BRR: 1.2% –3.5%), the reason for LLD treat-
ment was a history of familial hypercholesterolaemia. 
Statin monotherapy was the most commonly pre-
scribed LLD therapy (90.3%). Within regions, the 
proportions of patients on statin monotherapy were 
greater than 90%, with the exception of Asia (85.1%) 
and Western Europe (89.1%). Simvastatin was the 
most commonly used statin monotherapy, being pre-
scribed to 33.9% of all patients receiving statin mono-
therapy, followed by atorvastatin (32.9%) and rosuv-
astatin (20.2%).
LDL-C Goal Attainment
Fig.2 shows the proportions of patients attaining 
their 2004 updated NCEP ATP III LDLC goal 
according to sex, overall and by region. In total, 
49.4% of patients attained their LDLC goal. The pro-
portions of patients attaining their recommended 
LDL-C goal were higher than the overall proportion 
in Africa, Western Europe, and the Middle East 
(57.9%, 56.6%, and 52.4%, respectively). Poor con-
trol of LDL-C levels was most apparent in Eastern 
Europe, where only 26.0% of individuals had attained 
their desired LDL-C level. Overall and across all 
regions, the proportions of patients who attained their 
Table 2. Lipid-lowering drug treatment, overall and by region
Total
(n=35 121)
Asia
(n=7489)
Western Europe
(n=12 319)
Eastern Europe
(n=4654)
Middle East
(n=5850)
Africa
(n=4809)
Current treatment
Statin monotherapy
Atorvastatin
Fluvastatin
Lovastatin
Pitavastatin
Pravastatin
Rosuvastatin
Simvastatin
Fibrate monotherapy
Other monotherapy
Combination therapy＊
Reason for treatment
Primary prevention
Secondary prevention＊＊
Familial hypercholesterolaemia
Duration of treatment (years)
Mean±SD
31 299 (90.3)
10 775 (32.9)
900 (2.8)
226 (0.7)
145 (0.4)
1533 (4.7)
6614 (20.2)
11 106 (33.9)
1291 (3.7)
130 (0.4)
1941 (5.6)
19 478 (57.5)
13 631 (40.2)
763 (2.3)
3.9±3.9
6371 (85.1)
1863 (27.4)
154 (2.3)
84 (1.2)
145 (2.1)
165 (2.4)
1807 (26.6)
2153 (31.7)
404 (5.4)
23 (0.3)
687 (9.2)
3490 (47.7)
3714 (50.7)
116 (1.6)
2.9±3.0
10 650 (89.1)
3260 (28.6)
400 (3.5)
46 (0.4)
0 (0.0)
1164 (10.2)
2462 (21.6)
3318 (29.1)
658 (5.5)
90 (0.8)
559 (4.7)
7872 (66.2)
3690 (31.0)
336 (2.8)
4.9±4.5
4344 (93.8)
1516 (34.1)
47 (1.1)
85 (1.9)
0 (0.0)
90 (2.0)
1083 (24.4)
1523 (34.3)
98 (2.1)
3 (0.1)
187 (4.0)
2159 (46.6)
2395 (51.7)
81 (1.7)
3.1±3.3
5479 (93.8)
2445 (44.1)
74 (1.3)
7 (0.1)
0 (0.0)
51 (0.9)
705 (12.7)
2197 (39.7)
54 (0.9)
5 (0.1)
302 (5.2)
3752 (71.5)
1435 (27.3)
62 (1.2)
3.7±3.4
4455 (93.8)
1691 (37.2)
225 (5.0)
4 (0.1)
0 (0.0)
63 (1.4)
557 (12.3)
1915 (42.2)
77 (1.6)
9 (0.2)
206 (4.3)
2205 (46.2)
2397 (50.3)
168 (3.5)
3.1±2.9
SD= standard deviation.
Numbers are n (%) unless otherwise stated and are based on patients with non-missing data.
＊Combination therapy was simvastatin plus ezetimibe
＊＊Includes patients whose reason for treatment was diabetes mellitus.
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ceived importance of adherence were found to be sig-
nificantly associated with LDL-C goal attainment 
[answers to the following questions: I always take my 
tablets to lower my cholesterol every day (agree/disagree/
don’t know or not applicable) and How often do you 
think you can miss a tablet without affecting your choles-
terol levels ? (more than once a week/once a week/once 
every 2 weeks/once a month or less) from the patient 
questionnaire] (Fig.5).
Patients who were prescribed simvastatin, atorv-
astatin, or rosuvastatin were more likely to attain their 
recommended LDL-C level than those who were pre-
scribed any other LLD therapy. Rosuvastatin was asso-
ciated with the greatest likelihood of LDL-C goal 
attainment relative to any other LLD therapy (OR: 
1.81; 95% CI: 1.59 –2.06). The lower their CV risk, 
the more likely patients were to attain their LDL-C 
goal; individuals in the low and moderate CV risk cat-
egories were much more likely to attain their LDL-C 
goal than those in the very high CV risk category 
(OR: 235.48; 95% CI: 167.64 –330.78 and OR: 
85.14; 95% CI: 63.11 –114.86, respectively). Of the 
indications for LLD therapy that were assessed (pri-
mary prevention, secondary prevention, and familial 
likely to attain their LDL-C goal than men (OR: 0.71; 
95% CI: 0.65–0.77). Higher age was associated with 
better odds of attaining LDL-C goal (OR: 1.01; 95% 
CI: 1.01 –1.02 for a 1-year increase in age). Presence 
of diabetes mellitus, hypertension, or a history of CV 
disease was associated with a significant increase in the 
proportion of patients attaining their recommended 
LDL-C level. In contrast, current smokers and indi-
viduals with metabolic syndrome or a family history 
of early-onset CHD were less likely to attain their rec-
ommended LDL-C level than those without such CV 
risk factors (Fig.5).
The likelihood of attaining their LDL-C goal 
was greater in patients who had been given a LDL-C 
goal by their physician than in those who had not 
[answer to the following question: Did your doctor give 
you a target cholesterol level to aim for ? (yes/no) from 
the patient questionnaire]. Similarly, those who were 
satisfied with their treatment were more likely to 
attain their LDL-C goal than those who were not 
[answer to the following question: In general, do you 
feel satisfied about the way your high cholesterol has 
been treated ? (yes/no) from the patient questionnaire]. 
Patient-reported adherence to LLD therapy and per-
Fig.2. Proportions of patients attaining their LDL-C goal according to sex, overall and by region.
LDL-C goal attainment was assessed according to the 2004 updated US National Cholesterol Education Program Adult Treatment Panel III 
guidelines5). Numbers in brackets indicate the total number of patients in each category.
LDL-C= low-density lipoprotein cholesterol.
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approximately 55% and 23% of these patients having 
adequately controlled LDL-C levels, respectively.
This meta-analysis provides a global overview of 
hypercholesterolaemia treatment for the period when 
the studies were conducted (2006 –2010) based on a 
large number of patients of different ethnic origins. 
However, it has some limitations. The surveys were 
conducted in the same way in the different countries, 
but there may be considerable variability in clinical 
practice and reimbursement between regions, coun-
tries, and study sites. Moreover, only willing patients 
and physicians (selected based on having experience of 
treating dyslipidaemia) were included in the study 
cohort and it may therefore not be representative of 
general clinical practice, although these sources of bias 
would, if anything, lead to an overestimation of the 
proportion of patients attaining LDL-C goals. It 
hypercholesterolaemia) only secondary prevention was 
found to be associated with LDL-C goal attainment 
(OR: 1.24; 95% CI: 1.09–1.40).
Discussion
The combined results from CEPHEUS observa-
tional studies conducted in 29 countries across five 
regions highlight that LDL-C goal attainment in 
patients prescribed LLDs is poor worldwide. At the 
time of the surveys, ＜50% of patients attained their 
LDL-C goal despite having been on LLD therapy for 
a mean of 3.9 years. Lipid level control was good in 
patients at low CV risk, with approximately 90% of 
such patients attaining their recommended LDL-C 
level. In contrast, goal attainment was much lower in 
high and very high CV risk patients, with only 
Fig.3. Proportions of patients attaining their LDL-C goal according to CV risk, overall and by region.
CV risk profile and LDL-C goal attainment were assessed according to the 2004 updated US National Cholesterol Education Program Adult 
Treatment Panel III guidelines5). Numbers in brackets indicate the total number of patients in each category.
CV=cardiovascular; LDL-C= low-density lipoprotein cholesterol.
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a higher rate of LDL-C goal attainment than the com-
bined CEPHEUS studies. The L-TAP2 study was 
conducted in nine countries across Europe (France, 
Netherlands, and Spain), the Americas (USA, Canada, 
Brazil, and Mexico) and Asia (South Korea and Tai-
wan), and 73% of 9955 evaluated patients were shown 
to have attained their LDL-C goal. Although LLD 
therapy distributions were similar in both studies, it 
should be noted that there were more patients at low 
and moderate CV risk in the L-TAP2 study than in 
the CEPHEUS surveys (40.4% vs. 23.3%). Both 
studies reported better goal attainment in the low and 
moderate CV risk categories than in the higher CV 
risk category. Better LDL-C goal attainment was also 
observed for Japanese patients with low and moderate 
CV risk compared with those with a high CV risk in 
the large (N=22 121) Japan Lipid Assessment Pro-
gram (J-LAP) study31). Overall, LDL-C goal attain-
ment was substantially higher in the J-LAP study than 
in the CEPHEUS study (63.7% vs. 49.4%). As with 
the L-TAP2 study, this may be because of the higher 
proportion of patients with low and moderate CV risk 
that were included compared with CEPHEUS (55.7% 
should also be noted that the patient and physician 
questionnaires were not validated but used for explor-
atory purposes only. Finally, the surveys collected a 
limited amount of data. For example, data on dietary 
and other lifestyle interventions, adverse events, differ-
ences in healthcare policies, out-of-pocket costs, and 
patients’ socioeconomic status and level of education 
were not recorded. These factors may be determinants 
of LDL-C goal attainment and are, therefore, poten-
tial confounders in this study.
The results of the present study are in line with 
those reported by other studies worldwide. For exam-
ple, in the third European Action on Secondary Pre-
vention to Reduce Events (EUROASPIRE III) survey, 
57.3% of patients on LLDs were found to have 
attained their LDL-C goal18). The CEPHEUS results 
are also in line with those from the Return on Expen-
diture Achieved for Lipid Therapy in Asia (REALITY-
Asia) study, in which only 48% of 2622 patients with 
hypercholesterolaemia and newly initiated on statin 
monotherapy attained their NCEP ATP III goal for 
LDL-C after 12 months17). However, the Lipid Treat-
ment Assessment Project 2 (L-TAP2) study19), reported 
Fig.4. Proportions of patients attaining their LDL-C goal according to lipid-lowering therapy, overall and by region.
LDL-C goal attainment was assessed according to the 2004 updated US National Cholesterol Education Program Adult Treatment Panel III 
guidelines5). Numbers in brackets indicate the total number of patients in each category.
LDL-C= low-density lipoprotein cholesterol.
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in terms of the distribution of LLD therapy, with the 
exception that no patients in the J-LAP study were 
taking rosuvastatin compared with 12% of patients in 
the L-TAP2 study. This factor, among others, may 
have contributed to the higher rate of LDL-C goal 
vs. 23.3%). However, LDL-C goal attainment was not 
as high in the J-LAP study as it was in the L-TAP2 
study (63.7% vs. 73%), despite the higher proportion 
of low and moderate CV risk patients included in the 
former (55.7% vs. 40.4%). These studies were similar 
Fig.5. Determinants of LDL-C goal attainment based on 32 782 patients from 28 countries.
LDL-C goal attainment was assessed according to the 2004 updated US National Cholesterol Education Program Adult Treatment Panel III 
guidelines5).
＊Continuous variable (OR calculated for an increase of 1 year).
†Relative to absence of CV risk factor.
‡Question 4: Did your doctor give you a target cholesterol level to aim for ? (no/yes).
§Question 9: I am frustrated that I still do not know whether my tablets have been effective enough in lowering my cholesterol. (disagree/
agree).
¶Question 10: I always take my tablets to lower my cholesterol every day. (disagree/ agree).
‖Question 14: How often do you think you can miss a tablet without affecting your cholesterol levels ? (once a week/more than once a week).
＊＊Question 14: How often do you think you can miss a tablet without affecting your cholesterol levels ? (once a month or less/more than once 
a week).
††Question 16a: In general, do you feel satisfied about the way your high cholesterol has been treated ? (no/yes).
‡‡Relative to all other therapies.
§§Relative to all other indications.
¶¶Relative to very high CV risk.
CI=confidence interval; CHD=coronary heart disease; CV=cardiovascular; LDL-C= low-density lipoprotein cholesterol; LLD= lipid-lower-
ing drug; NCEP ATP III=US National Cholesterol Educational Program Adult Treatment Panel III; OR=odds ratio.
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studies worldwide and has been shown to be associ-
ated with increased CV morbidity and mortality34).
Among the potential factors studied to identify 
the determinants of LDL-C goal attainment, increas-
ing age was associated with better LDL-C control. 
The reason for this is unclear, but it should be noted 
that allocation of statin therapy (relative to any other 
LLD therapy) was higher in patients aged 55 years or 
older than in those aged 18 –39 years. Statins have 
been shown to be more efficacious than other current 
LLDs to lower LDL-C levels8), and this may explain, 
at least in part, the decreased likelihood of younger 
patients attaining their LDL-C goal compared with 
older individuals.
This study also highlighted a difference between 
men and women. Although the proportions of patients 
who attained their LDL-C goal were greater in women 
than in men overall (51.9% vs. 47.4%), the multivari-
ate adjusted analysis revealed that women were less 
likely than men to attain their goal. The reason for 
this difference is unclear, but a similar finding has 
been reported in several studies35-39). For example, in 
the NCEP Evaluation Project Utilizing Novel E-Tech-
nology (NEPTUNE) II, the adjusted OR for LDL-C 
goal attainment was 0.76 (95% CI: 0.62 –0.93) for 
women compared with men with CHD or CHD risk 
equivalents35). A similar sex disparity was observed in 
a Chinese study, with an adjusted OR of 0.77 (95% 
CI: 0.60 –0.90) for women relative to men in patients 
at high or very high CV risk36). Although differences 
in treatment between men and women have been sug-
gested to explain this disparity37-39), further research is 
required to understand and address this phenomenon.
Familial hypercholesterolaemia was not associ-
ated with a significant reduction in the prevalence of 
LDL-C goal attainment, with a similar rate observed 
compared with the overall study population (49.5% 
vs. 50.4%). This is despite familial hypercholesterolae-
mia typically being less responsive to cholesterol low-
ering methods. It may be that clinicians tend to treat 
patients with familial hypercholesterolaemia more 
aggressively, thus compensating for higher treatment 
resistance. Alternatively, patients with familial hyper-
cholesterolaemia may be more adherent. Indeed, the 
provision of genetic test information (required for the 
diagnosis of familial hypercholesterolaemia) has previ-
ously been shown to significantly improve adherence 
to LLDs40, 41). Further investigation of this patient 
sub-group may be warranted.
The three most common statin monotherapies 
used in the CEPHEUS studies (simvastatin, atorvas-
tatin, and rosuvastatin) were associated with an 
increased likelihood of LDL-C goal attainment, rela-
attainment in J-LAP vs. L-TAP2 because rosuvastatin 
has been shown to be more effective than at least one 
other statin (atorvastatin) for LDL-C goal attainment 
in Japanese patients32).
There are several potential explanations for the 
overall poor attainment of LDL-C goals observed in 
the CEPHEUS studies. Although 92.4% of physicians 
in these studies reported that they used clinical prac-
tice guidelines, particularly NCEP ATP III (used by 
50.7%), to set an individual patient’s treatment goal, 
only 71.2% of patients indicated they had been given 
a cholesterol goal. Given the positive association 
observed between patients’ awareness of their recom-
mended LDL-C level and attainment of that goal, 
more efforts are required from physicians to ensure 
that their patients are well informed about their treat-
ment goal. Similarly, there is room for improvement 
in patient education and information because only 
71.7% of patients reported having heard or been told 
about LDL-C and 37.9% did not know whether they 
had attained their recommended cholesterol level.
Another contributor to the low rate of goal 
attainment may be the fact that only a few patients 
were prescribed high-intensity statin therapy 33). 
Although 68.3% of individuals were at high or very 
high CV risk, only 5.3% and 3.5% of patients on 
LLD monotherapy were prescribed doses of atorvas-
tatin of at least 40 mg/day or doses of rosuvastatin of 
at least 20 mg/day, respectively. Most patients were on 
low- or medium-intensity statins, and the majority 
(63.2%) of the patients were still on the same LLD 
regimen as first prescribed. Drug dose had been 
increased for only 8.7% of patients since their first 
LLD prescription. Reasons for this conservative thera-
peutic approach are not clear, but may reflect patients’ 
or physicians’ concerns about possible higher risks of 
adverse events with higher doses of LLDs. Moreover, 
physicians may be reluctant to increase drug dosage if 
they think that failure to attain recommended choles-
terol goals is partly because of poor patient adherence 
and/or failure to implement recommended lifestyle 
changes. Other determinants of this clinical inertia 
may include disagreement with or insufficient knowl-
edge of the current guidelines.
Although patient non-adherence to treatment 
could be a factor in the low rate of LDL-C goal attain-
ment, adherence was not assessed by tablet counts or 
prescription records in the CEPHEUS studies. How-
ever, 35.3% of patients reported that they sometimes 
forgot to take their cholesterol-lowering tablets, and 
49.4% admitted forgetting to take their tablets once 
every 2 weeks or more often. This suboptimal adher-
ence to LLD therapy is in line with results from many 
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Q1  For what proportion of patients do you set individual target cholesterol levels expressed 
as an actual number? 
______% 
Q2  Which lab measures do you generally use to set individual target cholesterol levels? 
 You can give more than one answer. 
  Total cholesterol  HDL-C 
  LDL-C  Triglycerides 
Q3  Do you utilize any guidelines to help to establish individual cholesterol targets for your 
patients? 
  Yes  No 
 Â CONTINUE Â GO TO Q5 
Q4  a) Which guidelines do you use? 
 You can give more than one answer. 
 If you use more than one guideline, please answer the following question. 
 b) Which one do you mainly use? 
 Please select one answer only. 
 Use Mainly use
Joint European guidelines (SCORE)   
NCEP ATP III guidelines (FRAMINGHAM)   
National guidelines   
Local healthcare authority 
guidelines/recommendations   
Individual practice guidelines/recommendations   
Other (write in) 
____________________________________________   
Unable to name the precise guidelines used   
 
Q5  When patients are first diagnosed with hypercholesterolaemia, do you generally inform 
them of their cholesterol level? 
  Yes  No 
Supplemental Fig.1.
Questionnaire used to assess physicians' general attitudes toward the diagnosis of hypercholesterolemia, their percep-
tion of existing guidelines, and their knowledge about available treatment options
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Q6  In what proportions of patients do you: 
 a) not mention extent of reduction at all  ______% 
 b) provide a target cholesterol level expressed as an actual number ______% 
 c) provide a percentage or proportion reduction ______% 
 d) provide a more general description such as need to reduce by ‘a little’ 
  or ‘a lot’     ______% 
      a+b+c+d must add up to 100% 
Q7  When informing your patients, which of the following types of lipid parameters 
measurement do you generally use? 
 You can give more than one answer. 
  Total cholesterol  HDL-C 
  LDL-C   Triglycerides 
Q8  Focussing now on pharmacological treatment for hypercholesterolaemia, for what 
percentage of your patients do you recommend treatment with: 
 a) statins   ______% 
 b) fibrates   ______% 
 c) bile acid sequestrants   ______% 
 d) other   ______% 
    a+b+c+d must add up to 100% 
Q9  How frequently do you see the patient to review their cholesterol level? 
  Do not review 
  Less frequently than once per year 
 Once per year 
  Once every 6 months 
  Once every 3 months 
  More frequently than once every 3 months 
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 Please circle the most applicable number that meets how much you agree/disagree with 
each one (1 is disagree strongly and 5 is agree strongly). 
 The same scale will be used for all statements. 
 Disagree Agree 
strongly strongly
 General 
Q10 I feel frustrated that I am not always able to effectively 
treat my patients with cardiovascular disorders 1 2 3 4 5 
 Guidelines and goal 
Q11 I find it stressful trying to get my patients to their 
cholesterol targets 1 2 3 4 5 
Q12 I feel pressured to get patients to their target cholesterol 
level 1 2 3 4 5 
Q13 A sufficient number of patients reach their target 
cholesterol levels 1 2 3 4 5 
Q14 I’m frustrated that the guidelines instruct me to advise 
lifestyle changes alone as first-line therapy in all 
patients 
1 2 3 4 5 
Q15 I’m frustrated that the guidelines instruct me to 
prescribe a low dose of lipid-lowering drug to all 
patients and titrate upwards 
1 2 3 4 5 
 Pharmacological treatment 
Q16 I tend to prescribe a lipid-lowering drug only to patients 
who have proved they can adhere to diet and exercise 
change 
1 2 3 4 5 
Q17 Patient compliance decreases if lipid-lowering drugs 
take too long to have an effect 1 2 3 4 5 
Q18 I feel constrained to use less-effective lipid-lowering 
drugs first line 1 2 3 4 5 
Q19 Patients become concerned that their condition is more 
severe if their lipid-lowering drug is titrated up 1 2 3 4 5 
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Q20 Patients become concerned that their condition is more 
severe if their lipid-lowering drug is frequently changed 1 2 3 4 5 
 

Q21 In summary, thinking of all your hypercholesterolaemia patients, what percentage of 
those that have been set a target cholesterol level fall into the following categories? 
 a) Reached their target cholesterol level and continue to stay at this level ______% 
 b) Generally stay at their target cholesterol level but their cholesterol  
is sometimes too high   ______% 
 c) Reached their target cholesterol level in the past but have now relapsed ______% 
 d) Have never reached their target cholesterol level ______% 
             a+b+c+d must add up to 100% 
  Never set target cholesterol levels 
Q22 In general, once a patient has reached their target cholesterol level, after what length of 
time do you ask that patient to come back to review their hypercholesterolaemia? 
 ______ months 
  Never set target cholesterol levels 
Q23 What percentage of patients actually attends this review? 
 ______% 
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Q1  Have you heard of or been told about bad cholesterol, otherwise known as LDL-C? 
 Yes  No  Don’t know/Can’t remember 
Q2  Have you ever heard of or been told about good cholesterol, otherwise known as  
HDL-C? 
 Yes  No  Don’t know/Can’t remember 
Q3  When you were first told by your doctor that you had high cholesterol, did your doctor 
tell you what your cholesterol level was? 
  Yes  No 
 Â CONTNUE Â GO TO Q5 
Q4  Did your doctor give you a target cholesterol level to aim for? 
  Yes  No 
Q5  As a first step when you were diagnosed with high cholesterol, did the doctor: 
 Please select one answer only. 
  only advise you to change your lifestyle e.g. change your diet, stop smoking and/or 
do more exercise? 
  only prescribe a tablet? 
  both advise lifestyle changes and prescribe a tablet? 
  neither advise lifestyle changes nor prescribe a tablet? 
Q6  Which one of the following best describes the number of times your cholesterol-
lowering tablet has been changed since it was first prescribed? 
  Still on the same tablet 
 Â GO TO Q8 
  Still on the same tablet but the dose has increased 
 Â CONTINUE 
  Have changed tablets once or twice (may include adding another tablet) 
 Â CONTINUE 
  Have changed tablets several times (may also include adding other tablets) 
 Â CONTINUE 
Supplemental Fig.2.
Questionnaire used to assess patients' personal perceptions of hypercholesterolemia, their current lipid-lowering drug 
regimen, their adherence to this regimen, and their satisfaction with the treatment
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Q7  If Q6 = b, c or d 
 How did you feel about your cholesterol-lowering tablets having to be changed i.e. 
having the dose of your tablet increased or taking a different tablet? Please answer Yes 
or No to the following. 
 Yes No 
a) Satisfied   
b) Concerned that your condition was now a ‘serious illness’   
c) No strong feelings   
d) Less motivated to keep taking tablets   
e) Irritated at having to keep making changes   
f) Disappointed that treatment was not successful   
 
Q8  I am satisfied with the level of information available to me about high cholesterol. 
  Agree  Disagree Don’t know/Not applicable 
Q9  I am frustrated that I still do not know whether my tablets have been effective enough 
in lowering my cholesterol. 
  Agree  Disagree Don’t know/Not applicable 
Q10  I always take my tablets to lower my cholesterol every day. 
  Agree  Disagree Don’t know/Not applicable 
Q11  I stopped taking my tablets when my cholesterol level returned to normal. 
  Agree  Disagree Don’t know/Not applicable 
Q12  Sometimes I forget to take my cholesterol-lowering tablets. 
  Agree  Disagree Don’t know/Not applicable 
 Â CONTINUE Â GO TO Q14 Â GO TO Q14 
Q13  Approximately how often do you forget to take your cholesterol-lowering tablets? 
Please select the option which most closely applies to you. 
  More than once a week   Once a week 
  Once every 2 weeks  Once a month or less 
Q14  How often do you think you can miss a tablet without affecting your cholesterol levels?
  More than once a week   Once a week 
  Once every 2 weeks  Once a month or less 
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Q15  Which of the following best describes your current situation? 
  I have not been given a target cholesterol level 
  I have not reached my target cholesterol level 
  I’m not sure whether I have reached my target cholesterol level 
  I have reached my target cholesterol level 
Q16  In general, how do you feel about the way your high cholesterol has been treated? 
Please answer Yes or No to the following. 
 Yes No 
a) Satisfied   
b) Motivated   
c) Concerned   
d) Frustrated   
e) Disappointed   
f) Confused   
g) No strong feelings   
 
Q17  In general, how often do you see your doctor for a check-up of your cholesterol level? 
  More frequently than once every 3 months 
  Every 3 months 
 Every 6 months 
  Every year 
  Less often than once a year 
  Do not have check-ups 
  Don’t know/Can’t remember 
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